Cormorant Asset Management, LP has filed its 13F form on November 14, 2025 for Q3 2025 where it was disclosed a total value porftolio of $628 Million distributed in 36 stocks.
Among their holdings, we can observe that their the top five positions include companies like: Eye Point Pharmaceuticals, Inc. with a value of $115M, Bridge Bio Pharma, Inc. with a value of $72.7M, Edgewise Therapeutics, Inc. with a value of $65M, Arcellx, Inc. with a value of $63.6M, and Insmed Inc with a value of $61.9M.
Examining the 13F form we can see an decrease of $364M in the current position value, from $992M to 628M.
Cormorant Asset Management, LP is based out at Boston, MA
Below you can find more details about Cormorant Asset Management, LP portfolio as well as his latest detailed transactions.
